BR112018075901A2 - anticorpo humanizado ou fragmento de ligação a anticorpo, uso deste, complexo in vitro, opcionalmente isolado, e método in vitro - Google Patents

anticorpo humanizado ou fragmento de ligação a anticorpo, uso deste, complexo in vitro, opcionalmente isolado, e método in vitro

Info

Publication number
BR112018075901A2
BR112018075901A2 BR112018075901-5A BR112018075901A BR112018075901A2 BR 112018075901 A2 BR112018075901 A2 BR 112018075901A2 BR 112018075901 A BR112018075901 A BR 112018075901A BR 112018075901 A2 BR112018075901 A2 BR 112018075901A2
Authority
BR
Brazil
Prior art keywords
vitro
binding fragment
antibody
optionally isolated
complex
Prior art date
Application number
BR112018075901-5A
Other languages
English (en)
Inventor
Zeng Qi
Original Assignee
Agency For Science, Technology And Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency For Science, Technology And Research filed Critical Agency For Science, Technology And Research
Publication of BR112018075901A2 publication Critical patent/BR112018075901A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

a presente invenção diz respeito a anticorpos humanizados que se ligam à fosfatase de regeneração de fígado 3 (prl3) e uso de ditos anticorpos para o tratamento de câncer. também é reivindicado um método in vitro para determinar a localização celular de prl3 em uma célula, em que a expressão de prl3 na superfície celular indica que a célula é cancerígena.
BR112018075901-5A 2016-06-14 2017-06-14 anticorpo humanizado ou fragmento de ligação a anticorpo, uso deste, complexo in vitro, opcionalmente isolado, e método in vitro BR112018075901A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10201604834P 2016-06-14
SG10201604834P 2016-06-14
PCT/SG2017/050300 WO2017217934A1 (en) 2016-06-14 2017-06-14 Prl3 antibody

Publications (1)

Publication Number Publication Date
BR112018075901A2 true BR112018075901A2 (pt) 2019-03-19

Family

ID=60663634

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018075901-5A BR112018075901A2 (pt) 2016-06-14 2017-06-14 anticorpo humanizado ou fragmento de ligação a anticorpo, uso deste, complexo in vitro, opcionalmente isolado, e método in vitro

Country Status (10)

Country Link
US (1) US11155636B2 (pt)
EP (1) EP3469003A4 (pt)
JP (2) JP2019531254A (pt)
KR (1) KR102451588B1 (pt)
CN (1) CN109476759B (pt)
AU (1) AU2017285995B2 (pt)
BR (1) BR112018075901A2 (pt)
CA (1) CA3025756A1 (pt)
SG (1) SG11201811068YA (pt)
WO (1) WO2017217934A1 (pt)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050287644A1 (en) 2004-05-14 2005-12-29 Genesis Biotech Inc. Methods for producing and culturing rabbit-mouse hybridomas and monoclonal antibodies secreted by rabbit-mouse hybridomas
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
EP1848742A1 (en) 2005-01-28 2007-10-31 Attogen, Inc. Anti-prl-3 antibodies and methods of use thereof
EP2529754A1 (en) * 2007-05-03 2012-12-05 Agency For Science, Technology And Research (A*star) Antibodies binding to an intracellular PRL-1 or PRL-3 polypeptide
EP2347038A4 (en) * 2008-10-14 2013-06-12 Janssen Biotech Inc METHOD FOR HUMANIZATION AND AFFINITY TREATMENT OF ANTIBODIES
CN102753191B (zh) 2009-11-30 2016-08-24 新加坡科技研究局 通过抗体疗法或接种治疗和预防与细胞内癌蛋白相关的癌症
US20170146538A1 (en) 2014-02-07 2017-05-25 Agency For Science, Technology And Research Prl-3 as a biomarker for the prognosis of cancer and a target for therapy

Also Published As

Publication number Publication date
KR20190024961A (ko) 2019-03-08
AU2017285995A1 (en) 2019-01-31
JP2022078202A (ja) 2022-05-24
CN109476759A (zh) 2019-03-15
EP3469003A4 (en) 2020-07-29
CA3025756A1 (en) 2017-12-21
US20200181283A1 (en) 2020-06-11
CN109476759B (zh) 2022-11-08
US11155636B2 (en) 2021-10-26
KR102451588B1 (ko) 2022-10-06
JP2019531254A (ja) 2019-10-31
SG11201811068YA (en) 2019-01-30
WO2017217934A1 (en) 2017-12-21
EP3469003A1 (en) 2019-04-17
AU2017285995B2 (en) 2023-11-30
JP7408707B2 (ja) 2024-01-05

Similar Documents

Publication Publication Date Title
BR112019000327A8 (pt) Anticorpo para anticlaudina 18a2 e uso do mesmo
UY37928A (es) Anticuerpos anti-cd38 y métodos de uso
CL2022002448A1 (es) Constructos de anticuerpo para flt3 y cd3 (divisional sol.: 201800269)
BR112018000768A2 (pt) anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos
BR112019011186A2 (pt) conjugado de anticorpo radiomarcado, composto, e, métodos de imageamento e para tratamento de um tumor.
ECSP17054182A (es) Anticuerpos anti-CD3, anticuerpos anti-CD123 y anticuerpos biespecíficos que se unen específicamente a CD3 y/o CD123
MX2020001879A (es) Proteínas de fijación al antígeno que se dirigen a antígenos compartidos.
DOP2018000045A (es) Anticuerpos pd-l1
AR101846A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
BR112018002844A2 (pt) receptores de antígeno quimérico à base de anticorpos de domínio único e métodos de uso dos mesmos
BR112017006468A2 (pt) anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer
EA201890383A1 (ru) Конструкции биспецифических антител, связывающиеся с мезотелином и кд3 (cd3)
BR112018000696A2 (pt) ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit?
EA201890382A1 (ru) Конструкции антител для cd70 и cd3
CO2018014325A2 (es) Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso
BR112016020752A2 (pt) ?anticorpo isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, e, métodos para tratamento de um câncer ou tumor expressando egfrviii e para tratamento de um câncer, redução de crescimento de tumor e/ou causação de regressão de tumor em um paciente?
BR112015007672A2 (pt) anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
BR112015022123A8 (pt) Anticorpos, fragmentos de ligação ao antígeno dos mesmos que se ligam especificamente à hepcidina ou um peptídeo de hepcidina, uso, meio contentor e kit
BR112019010595A2 (pt) anticorpo ou fragmento de ligação ao antígeno do mesmo, combinação de moléculas de ácido nucleico isoladas, composição farmacêutica, kit, e, método para selecionar um composto.
BR112013021562A2 (pt) anticorpos para cd70
BR112018070948A2 (pt) anticorpos anti-psma e utilização dos mesmos
BR112018072066A2 (pt) moléculas de ligação específicas para fcgamariia e uso das mesmas
BR112017001782A2 (pt) fragmentos de anticorpo radiomarcados para uso na prevenção e/ou tratamento de câncer
BR112019008279A2 (pt) uso de beta-catenina como um biomarcador para tratamento de cânceres usando anticorpo anti-dkk-1
MX2017009680A (es) Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d).

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]